Although whether or not a reduction in urinary L-FABP is commonly observed in patients with type 2 diabetes treated with SGLT2 inhibitors is unclear, patients showing a reduction in both the uACR and urinary L-FABP may have a better prognosis with regard to DKD than those without such reductions. The gene discussed is SLC5A2; the disease is diabetic kidney disease.